288. 自己免疫性後天性凝固因子欠乏症 Autoimmune acquired coagulation factor deficiency Clinical trials / Disease details
臨床試験数 : 205 / 薬物数 : 238 - (DrugBank : 31) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04344860 (ClinicalTrials.gov) | June 4, 2021 | 9/4/2020 | Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial | Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Acid vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial | Von Willebrand Diseases;Postpartum Hemorrhage | Drug: Recombinant Von Willebrand factor;Drug: Tranexamic Acid Injection [Cyklokapron] | Margaret Ragni | NULL | Recruiting | 18 Years | N/A | Female | 20 | Phase 3 | United States |
| 2 | NCT04146376 (ClinicalTrials.gov) | October 12, 2019 | 29/10/2019 | Von Willebrand Factor in Pregnancy (VIP) Study | Von Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of Wilate Use in Von Willebrand Disease for Childbirth | Von Willebrand Diseases | Other: Use of a postpartum diary and additional blood draws;Drug: VWF replacement therapy with Wilate;Drug: Tranexamic acid;Other: Use of a postpartum diary and additional blood draws. | Bloodworks | Mary M. Gooley Hemophilia Center;Ergomed;Octapharma | Recruiting | 18 Years | N/A | Female | 110 | United States | |
| 3 | NCT02606045 (ClinicalTrials.gov) | February 7, 2019 | 5/11/2015 | Minimize Menorrhagia in Women With Von Willebrand Disease | Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study | Von Willebrand Diseases | Drug: recombinant von Willebrand factor;Drug: tranexamic acid | Margaret Ragni | University of North Carolina;Duke University | Active, not recruiting | 13 Years | 45 Years | Female | 60 | Phase 3 | United States |
| 4 | NCT01800435 (ClinicalTrials.gov) | October 2011 | 15/2/2013 | A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor | Whole Blood Clot Stability and Thrombin Generating Capacity Following Treatment With Bypassing Agents (BPA) With and Without and Tranexamic Acid (TXA) in Haemophilia A Patients With inhibitor-an In-vivo Prospective Crossover Study | Hereditary Factor VIII Deficiency Disease With Inhibitor | Drug: aPCC, aPCC + TXA;Drug: rFVIIa, rFVIIa + TXA | Oslo University Hospital | NULL | Completed | 18 Years | 65 Years | Male | 6 | Phase 4 | Norway |
| 5 | NCT00111215 (ClinicalTrials.gov) | January 2001 | 18/5/2005 | Treatment and Management of Women With Bleeding Disorders | Treatment and Management of Women With Bleeding Disorders | Menorrhagia;Blood Coagulation Disorders;Blood Platelet Disorders;Von Willebrand Disease;Hematologic Disease | Drug: Tranexamic Acid;Drug: Desmopressin Acetate | Centers for Disease Control and Prevention | NULL | Completed | 18 Years | 50 Years | Female | 100 | N/A | United States |